Although further studies are currently underway (for example, NCT02363738 and NCT02473289), results from the RCT by Raison et al.20 included in this meta-analysis showed beneficial effects of infliximab for treatment-resistant depression cases only in those with elevated serum CRP levels at baseline. This evidence concerns the gene CRP and depressive disorder.